Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 9:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Buprenorphine/Naloxone high dose Clear all
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Low-dose Versus a High-dose Sublingual Buprenorphine Induction

NCT05944952
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
buprenorphine/naloxone
Drug
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dundalk, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 28, 2026, 9:20 PM EDT
Completed Phase 3 Interventional Results available

Medication Treatment for Opioid Use Disorder in Expectant Mothers

NCT03918850
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy
Interventions
Buprenorphine Injection, Buprenorphine Sublingual Product
Drug
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
12
States / cities
Jacksonville, Florida • Boston, Massachusetts • Albuquerque, New Mexico + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 28, 2026, 9:20 PM EDT
Completed Phase 4 Interventional Results available

Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence

NCT01903005
View directory record Official record
Conditions
Opioid Dependence, on Agonist Therapy
Interventions
Higher bioavailability BNX sublingual tablets
Drug
Lead sponsor
Orexo AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
28
States / cities
Jefferson County, Alabama • Marion County, Alabama • Winston County, Alabama + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Sep 28, 2026, 9:20 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Computer Delivered Community Reinforcement Approach (CRA) (Bup II)

NCT00929253
View directory record Official record
Conditions
Opiate Addiction
Interventions
Suboxone, CRA, Therapy, CM
Drug · Behavioral
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Sep 28, 2026, 9:20 PM EDT
Completed Phase 4 Interventional Results available

Starting Treatment With Agonist Replacement Therapies (START)

NCT00315341
View directory record Official record
Conditions
Opiate-related Disorders
Interventions
Buprenorphine/naloxone, Methadone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
1,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
9
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Sep 28, 2026, 9:20 PM EDT
Completed No phase listed Observational

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study

NCT03911466
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy
Interventions
Buprenorphine Injection, Buprenorphine Sublingual Product
Drug
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
12
States / cities
Jacksonville, Florida • Boston, Massachusetts • Albuquerque, New Mexico + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 28, 2026, 9:20 PM EDT
Terminated Phase 4 Interventional Results available

Evaluating the Use of Sublingual Sufentanil in Patients With Suboxone Treatment

NCT04716413
View directory record Official record
Conditions
Acute Pain
Interventions
Dsuvia
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Sep 28, 2026, 9:20 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder

NCT02559973
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
RBP-6000, SUBOXONE Sublingual Film
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Sep 28, 2026, 9:20 PM EDT
Completed Phase 1 Interventional

Single Ascending Dose Study of RBP-6000

NCT03002961
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
RBP-6000, Suboxone
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 25, 2016 · Synced Sep 28, 2026, 9:20 PM EDT
Completed No phase listed Observational

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study

NCT03911739
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome, Drug Abuse in Pregnancy
Interventions
Buprenorphine Injection, Buprenorphine Sublingual Product
Drug
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
Not listed
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Jacksonville, Florida • Boston, Massachusetts • Portland, Oregon + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 28, 2026, 9:20 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Abuse Liability of Suboxone Versus Subutex

NCT00710385
View directory record Official record
Conditions
Opioid-related Disorders
Interventions
Heroin, Naloxone, Low Bup Dose, High Bup Dose, Low Bup/Nal Dose, High Bup/Nal Dose, Placebo (PCB)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Sep 28, 2026, 9:20 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Buprenorphine Induction for Fentanyl Dependent Opioid Users

NCT04794790
View directory record Official record
Conditions
Opioid Dependence Fentanyl
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Harrisburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Sep 28, 2026, 9:20 PM EDT
Recruiting Phase 3 Interventional

Standard Versus High Dose ED-Initiated Buprenorphine Induction

NCT06494904
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Oakland, California • San Leandro, California • Portland, Maine + 2 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 28, 2026, 9:20 PM EDT
Active, not recruiting Phase 2 Interventional

Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

NCT04464980
View directory record Official record
Conditions
Opioid Use Disorder (OUD)
Interventions
SL-BUP, XR-BUP, XR-NTX, MM, MMR, MMD
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
1,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
21
States / cities
Little Rock, Arkansas • Tarzana, California • Bridgeport, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 28, 2026, 9:20 PM EDT
Completed Phase 3 Interventional Results available

Buprenorphine Treatment for Opioid Dependence

NCT02187198
View directory record Official record
Conditions
Opioid Dependence
Interventions
Buprenorphine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Sep 28, 2026, 9:20 PM EDT
Recruiting Early Phase 1 Interventional

A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use

NCT06726200
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine + naloxone (Suboxone), Buprenorphine Injection
Drug
Lead sponsor
Rachel R. Luba
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 28, 2026, 9:20 PM EDT
Completed Phase 1Phase 2 Interventional

Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence

NCT03015246
View directory record Official record
Conditions
Heroin Dependence, Opioid Use Disorder
Interventions
Extended release morphine, Buprenorphine/Naloxone low dose, Buprenorphine/Naloxone moderate dose, Buprenorphine/Naloxone high dose, Active stressor, Placebo stressor
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Sep 28, 2026, 9:20 PM EDT